Corient Private Wealth LP Acquires New Holdings in Omnicell, Inc. $OMCL

Key Points

• Corient Private Wealth LP initiated a 62,810-share position in Omnicell during the second quarter, valued at approximately $2.6 million. Institutional investors collectively own about 97.7% of the company.
• Analyst sentiment is broadly positive, with seven Buy ratings, one Hold and one Sell; Omnicell has a consensus “Moderate Buy” rating and a $57.86 price target, despite Zacks Research downgrading the stock to “Strong Sell.”
• Omnicell exceeded quarterly earnings expectations, reporting $0.94 EPS versus a $0.47 consensus and $312.21 million in revenue, up 7.4% year over year. Shares opened at $34.71, well below their 52-week high of $55.00.

Corient Private Wealth LP bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 62,810 shares of the company's stock, valued at approximately $2,608,000. Corient Private Wealth LP owned about 0.14% of Omnicell at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Dana Investment Advisors Inc. purchased a new stake in Omnicell in the 4th quarter valued at approximately $3,445,000. Bank of America Corp DE increased its position in Omnicell by 31.3% during the first quarter. Bank of America Corp DE now owns 580,875 shares of the company's stock worth $19,390,000 after buying an additional 138,537 shares in the last quarter. Jackson Creek Investment Advisors LLC purchased a new position in Omnicell during the fourth quarter worth $2,022,000. BlackRock Inc. acquired a new position in shares of Omnicell in the second quarter worth $313,044,000. Finally, Dimensional Fund Advisors LP lifted its position in shares of Omnicell by 6.0% in the first quarter. Dimensional Fund Advisors LP now owns 2,450,385 shares of the company's stock valued at $81,791,000 after acquiring an additional 137,834 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on the company. Zacks Research lowered Omnicell from a "hold" rating to a "strong sell" rating in a research note on Friday, August 7th. Wall Street Zen raised shares of Omnicell from a "buy" rating to a "strong-buy" rating in a research note on Sunday, May 10th. Weiss Ratings upgraded shares of Omnicell from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, August 18th. Wells Fargo & Company decreased their price target on shares of Omnicell from $55.00 to $50.00 and set an "overweight" rating on the stock in a research note on Friday, July 31st. Finally, KeyCorp reiterated an "overweight" rating on shares of Omnicell in a report on Monday, August 24th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Omnicell presently has a consensus rating of "Moderate Buy" and a consensus price target of $57.86.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $34.71 on Thursday. The company has a market cap of $1.58 billion, a P/E ratio of 41.32, a P/E/G ratio of 0.87 and a beta of 0.97. The business has a fifty day simple moving average of $39.55 and a 200-day simple moving average of $39.29. Omnicell, Inc. has a 52 week low of $29.06 and a 52 week high of $55.00. The company has a quick ratio of 1.43, a current ratio of 1.64 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its earnings results on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping the consensus estimate of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million for the quarter, compared to the consensus estimate of $310.21 million. During the same period in the prior year, the business posted $0.45 earnings per share. The firm's revenue for the quarter was up 7.4% compared to the same quarter last year. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Equities research analysts forecast that Omnicell, Inc. will post 1.41 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company's offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell's analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source